All updated as on -
The market for hereditary testing was estimated to be worth USD 6.69 billion in 2022, and from 2023 to 2030, it is anticipated to expand at a CAGR of 9.4%.
One of the main market drivers is the growing field of reproductive genetic health. Important players like Natera have reported a consistent rise in test volumes for inherited disorders in women's health. This indicates the population's rising acceptance of hereditary tests, which has sped up revenue growth. COVID-19 had a negative effect on the marketplace. For instance, governments all across the world implemented lockdowns as a preventative measure after the World Health Organization designated COVID-19 a pandemic. This led to upheaval, limitations, difficulties, and adaptations in every field.
Similar to this, the pandemic had a negative effect on the field of inherited genetic analysis. This is because genetic counselors are unable to meet with clients in person, doctors are unable to offer advice, and the laboratory is unable to do the necessary tests. Genetic counselors were also unable to work during government shutdowns because regulatory agencies like the Centers for Medicaid Services (CMS) did not recognize them as healthcare professionals. Clinics also restricted in-person diagnostic procedures to slow the spread of the illness. Nevertheless, colossal providers of genetic testing like GeneDx offered clinician-ordered genetic screening as a service. Genetic counseling was given via telemedicine by both clinics and individual patients.
DNA screening kit purchases have surged as a result of the rise in the demand for genetic testing. For instance, in November 2019, the Virginia Department of General Services Division of Integrated Laboratory Facilities examined 7,867 babies for over 31 genetic and metabolic disorders. The market is expanding since newborn screening is being used more often globally. Due to modifications made to genetic testing protocols, multigene panel screening has become more prevalent in clinics for inherited illnesses. Additionally, encouraging government-sponsored programs are anticipated to further fuel industry expansion. For instance, the Netherlands' Ministry of Health, Welfare, and Sport said in March 2023 that beginning on April 1, 2023, all pregnant women in the nation would be able to take the NIPT test.The market expansion is anticipated to be greatly aided by this aggressive action.
Over the past 18 months, many industries have been adversely squeezed around the globe. This can be explained by the considerable disruptions that these lockdowns and other limitations imposed on businesses around the world caused to their particular manufacturing and supply-chain operations. Furthermore, since people are now more motivated to cut non-essential costs from their own budgets, consumer demand has also subsequently decreased. The general economic situation of the majority of people has been adversely impacted by this outbreak. Over the anticipated time frame, it is expected that the aforementioned factors will have a negative impact on the revenue trajectory of the worldwide hereditary testing market.
With a sizeable revenue share in 2022, the molecular testing sector became the leading force in the market. According to projections, this category will continue to grow impressively over the anticipated time, exceeding all other segments. In the upcoming years, market participants' strategic initiatives and the growing use of molecular testing for genetic disease diagnosis and screening are likely to drive the segment's growth.
In genetic testing, cytogenetic technology is essential because it makes it possible to examine chromosomal abnormalities and structural changes in the genome. In the market for hereditary testing, it is one of the most promising technologies. One of the main factors driving the expansion of this market during the anticipated period is the increasing use of cytogenetic tests for cancer detection and their cost-effectiveness when compared to alternative technologies.
Report Coverage
Global Hereditary Testing research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Hereditary Testing report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Hereditary Testing competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Hereditary Testing market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Hereditary Testing market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Hereditary Testing market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
CENTOGENE N.V. (Germany), Ambry Genetics (U.S.), Myriad Genetics, Inc. (U.S.), NeoGenomics Laboratories (U.S.), Quest Diagnostics Incorporated (U.S.), PreventionGenetics (U.S.), Fulgent Genetics (U.S.), Invitae Corporation (U.S.), Medical Diagnostic Laboratories, L.L.C. (U.S.), Natera (U.S.), Caris Life Sciences (U.S.), LabSolutions (U.S.), Progenity Inc. (U.S.), ARUP Laboratories (U.S.), Twist Bioscience, MedGenome, COOPERSURGICAL, INC., Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., SOPHiA GENETICS.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Hereditary Testing market based on the below-mentioned segments:
Global Hereditary Testing Market, By Type
Multi Panel Test
Single-site Genetic Test
Global Hereditary Testing market, By Indication
Breast Cancer
Ovarian Cancer
Colorectal Cancer
Others
Global Hereditary Testing Market, By End User
Diagnostic Laboratory
Hospitals
Others
Global Hereditary Testing market, Regional Analysis
One of the main market drivers is the growing field of reproductive genetic health. Important players like Natera have reported a consistent rise in test volumes for inherited disorders in women's health. This indicates the population's rising acceptance of hereditary tests, which has sped up revenue growth. COVID-19 had a negative effect on the marketplace. For instance, governments all across the world implemented lockdowns as a preventative measure after the World Health Organization designated COVID-19 a pandemic. This led to upheaval, limitations, difficulties, and adaptations in every field.
Similar to this, the pandemic had a negative effect on the field of inherited genetic analysis. This is because genetic counselors are unable to meet with clients in person, doctors are unable to offer advice, and the laboratory is unable to do the necessary tests. Genetic counselors were also unable to work during government shutdowns because regulatory agencies like the Centers for Medicaid Services (CMS) did not recognize them as healthcare professionals. Clinics also restricted in-person diagnostic procedures to slow the spread of the illness. Nevertheless, colossal providers of genetic testing like GeneDx offered clinician-ordered genetic screening as a service. Genetic counseling was given via telemedicine by both clinics and individual patients.
DNA screening kit purchases have surged as a result of the rise in the demand for genetic testing. For instance, in November 2019, the Virginia Department of General Services Division of Integrated Laboratory Facilities examined 7,867 babies for over 31 genetic and metabolic disorders. The market is expanding since newborn screening is being used more often globally. Due to modifications made to genetic testing protocols, multigene panel screening has become more prevalent in clinics for inherited illnesses. Additionally, encouraging government-sponsored programs are anticipated to further fuel industry expansion. For instance, the Netherlands' Ministry of Health, Welfare, and Sport said in March 2023 that beginning on April 1, 2023, all pregnant women in the nation would be able to take the NIPT test.The market expansion is anticipated to be greatly aided by this aggressive action.
Over the past 18 months, many industries have been adversely squeezed around the globe. This can be explained by the considerable disruptions that these lockdowns and other limitations imposed on businesses around the world caused to their particular manufacturing and supply-chain operations. Furthermore, since people are now more motivated to cut non-essential costs from their own budgets, consumer demand has also subsequently decreased. The general economic situation of the majority of people has been adversely impacted by this outbreak. Over the anticipated time frame, it is expected that the aforementioned factors will have a negative impact on the revenue trajectory of the worldwide hereditary testing market.
With a sizeable revenue share in 2022, the molecular testing sector became the leading force in the market. According to projections, this category will continue to grow impressively over the anticipated time, exceeding all other segments. In the upcoming years, market participants' strategic initiatives and the growing use of molecular testing for genetic disease diagnosis and screening are likely to drive the segment's growth.
In genetic testing, cytogenetic technology is essential because it makes it possible to examine chromosomal abnormalities and structural changes in the genome. In the market for hereditary testing, it is one of the most promising technologies. One of the main factors driving the expansion of this market during the anticipated period is the increasing use of cytogenetic tests for cancer detection and their cost-effectiveness when compared to alternative technologies.
Report Coverage
Global Hereditary Testing research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Hereditary Testing report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Hereditary Testing competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Hereditary Testing market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | CENTOGENE N.V. (Germany), Ambry Genetics (U.S.), Myriad Genetics, Inc. (U.S.), NeoGenomics Laboratories (U.S.), Quest Diagnostics Incorporated (U.S.), PreventionGenetics (U.S.), Fulgent Genetics (U.S.), Invitae Corporation (U.S.), Medical Diagnostic Laboratories, L.L.C. (U.S.), Natera (U.S.), Caris Life Sciences (U.S.), LabSolutions (U.S.), Progenity Inc. (U.S.), ARUP Laboratories (U.S.), Twist Bioscience, MedGenome, COOPERSURGICAL, INC., Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., SOPHiA GENETICS. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Hereditary Testing Market from 2021 to 2030.
- Market Forecast for Hereditary Testing Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Hereditary Testing competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Hereditary Testing
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Hereditary Testing market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Hereditary Testing market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
CENTOGENE N.V. (Germany), Ambry Genetics (U.S.), Myriad Genetics, Inc. (U.S.), NeoGenomics Laboratories (U.S.), Quest Diagnostics Incorporated (U.S.), PreventionGenetics (U.S.), Fulgent Genetics (U.S.), Invitae Corporation (U.S.), Medical Diagnostic Laboratories, L.L.C. (U.S.), Natera (U.S.), Caris Life Sciences (U.S.), LabSolutions (U.S.), Progenity Inc. (U.S.), ARUP Laboratories (U.S.), Twist Bioscience, MedGenome, COOPERSURGICAL, INC., Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., SOPHiA GENETICS.
Primary Target Market
- Market Players of Hereditary Testing
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Hereditary Testing market based on the below-mentioned segments:
Global Hereditary Testing Market, By Type
Multi Panel Test
Single-site Genetic Test
Global Hereditary Testing market, By Indication
Breast Cancer
Ovarian Cancer
Colorectal Cancer
Others
Global Hereditary Testing Market, By End User
Diagnostic Laboratory
Hospitals
Others
Global Hereditary Testing market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive hereditary testing market market research and competitor analysis for your business to help you develop more profound insights into the hereditary testing market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the hereditary testing market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.